动脉瘤性蛛网膜下腔出血(aneurysmal subarachnoid hemorrhage,a SAH)是颅内出血的一个重要类型,占脑血管总发生率的12%~20%。随着血管内介入及外科手术治疗对蛛网膜下腔出血的早期干预,动脉瘤再破裂出血的发生率明显降低,而脑血管痉挛所导致的迟发性脑缺血,尤其是脑梗死逐渐成为影响其预后的主要因素,目前尚无有效的治疗手段[1]。近年来越来越多的证据表明他汀类药物能够 Aneurysmal subarachnoid hemorrhage (a SAH) is an important type of intracranial hemorrhage, accounting for 12% to 20% of the total incidence of cerebrovascular disease. With the early intervention of endovascular intervention and surgical treatment of subarachnoid hemorrhage, the incidence of aneurysm rebleeding bleed was significantly reduced, and delayed cerebral ischemia caused by cerebral vasospasm, especially cerebral infarction, gradually became The main factors affecting their prognosis, there is no effective treatment [1]. There is increasing evidence in recent years that statins are able